Prohance Multipack Patent Expiration

Prohance Multipack is a drug owned by Bracco Diagnostics Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 08, 2015. Details of Prohance Multipack's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5846519 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2015

(8 years ago)

Expired
US5474756 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

Expired
US6143274 Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Prohance Multipack is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prohance Multipack's family patents as well as insights into ongoing legal events on those patents.

Prohance Multipack's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prohance Multipack's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 08, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prohance Multipack Generics:

There are no approved generic versions for Prohance Multipack as of now.

Alternative Brands for Prohance Multipack

Prohance Multipack which is used for enhancing visibility of tissues and organs during magnetic resonance imaging., has several other brand drugs using the same active ingredient (Gadoteridol). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Bracco
Prohance






About Prohance Multipack

Prohance Multipack is a drug owned by Bracco Diagnostics Inc. It is used for enhancing visibility of tissues and organs during magnetic resonance imaging. Prohance Multipack uses Gadoteridol as an active ingredient. Prohance Multipack was launched by Bracco in 2003.

Approval Date:

Prohance Multipack was approved by FDA for market use on 09 October, 2003.

Active Ingredient:

Prohance Multipack uses Gadoteridol as the active ingredient. Check out other Drugs and Companies using Gadoteridol ingredient

Treatment:

Prohance Multipack is used for enhancing visibility of tissues and organs during magnetic resonance imaging.

Dosage:

Prohance Multipack is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
279.3MG/ML INJECTABLE Prescription INJECTION